Lung Cancer

Patients with advanced non–small-cell lung cancer benefit mainly from chemotherapy using cisplatin (Platinol)-based combinations. Platinum compounds, however, due to their toxicity profile, have limited use in combination

The development of effective and well-tolerated combinations of chemotherapy and radiotherapy is of great importance to improve disease-free survival in patients treated for non–small-cell lung cancer. Studies

Many physicians have questioned whether the additional survival benefit gained from the use of combination chemotherapy in non–small-cell lung cancer has been offset by chemotherapy-induced toxicity, particularly with

Combined-modality approaches integrating carboplatin (Paraplatin) and low doses of weekly paclitaxel (Taxol) with thoracic radiation therapy for prolonging survival in patients with locally advanced non–small-cell lung cancer

New treatment strategies for small-cell lung cancer patients are required, as there have been few developments in the past 20 years. Paclitaxel (Taxol) has been shown to be effective in non–small-cell lung cancer when given in

Despite the availability of combination chemotherapy, response rates are poor in patients with non–small-cell lung cancer. Recently, phase II trials have been undertaken with single-agent paclitaxel (Taxol). Good results have

Despite a response rate of only 9%, single-agent carboplatin (Paraplatin) produced the best 1-year survival rate with the lowest toxicity in a five-arm Eastern Cooperative Oncology Group study of cisplatin (Platinol)

The combination regimen of paclitaxel (Taxol) and cisplatin (Platinol) for non–small-cell lung cancer has shown improved response rates in some phase II trials, and because of its safety profile, it could offer patients with this

Despite growing evidence that patients with advanced non–small-cell lung cancer have improved survival and better symptom control with modern systemic therapy, there is still resistance to the use of chemotherapy because

The effectiveness of paclitaxel (Taxol) in a range of tumors has been established in a large number of trials. In non–small-cell lung cancer, paclitaxel combined with cisplatin (Platinol) has been shown to be highly effective.

The activity and toxicity profiles of carboplatin (Paraplatin) and paclitaxel (Taxol) used as single agents in non–small-cell lung cancer made them logical agents for study in combination therapy. Once preliminary trials

In the 1980s, the introduction of cisplatin (Platinol)-based chemotherapy prolonged survival and improved quality of life in patients with stage III and IV non–small-cell lung cancer. More recently, the use of five new

In an attempt to further improve the quality of life and prognosis of patients with non–small-cell lung cancer, several clinical strategies exist to evaluate newer chemotherapy agents for this disease. Several of these

According to the results of a landmark phase III, multicenter, Southwest Oncology Group clinical trial (SWOG 9509), the use of paclitaxel (Taxol) plus carboplatin (Paraplatin) can be considered a standard regimen for non–small-cell lung cancer

NEW YORK-Screening of smokers with helical (spiral) low-dose computed tomography (CT) is more likely than chest x-rays to find malignant tumors, and the tumors are “substantially smaller than those detected on chest radiography,” said Claudia I. Henschke, MD, of New York Presbyterian Hospital-Weill Cornell Medical Center.

Gordon and Vokes present a comprehensive review of the management of locally advanced non-small-cell lung cancer (NSCLC). They summarize historical data on sequential and concurrent chemoradiation, as well as altered radiation

The article by Drs. Gordon and Vokes provides the reader with a comprehensive overview of the treatment of locally advanced unresectable non–small-cell lung cancer (NSCLC) with chemotherapy and radiation therapy. The authors

The optimal therapy for locally advanced, unresectable, stage III non–small-cell lung cancer (NSCLC) continues to evolve. The critical determinants of overall survival include local tumor control and the

PHILADELPHIA-Research shows that genetic makeup may offer a clue to an individual’s affinity for smoking and propensity to develop lung cancer, investigators said at the annual meeting of the American Association for Cancer Research (AACR).

A phase II study of combined-modality treatment consisting of uracil and tegafur (in a molar ratio of 4:1 [UFT]) plus cisplatin (Platinol) and concurrent radiotherapy was conducted to evaluate the activity of this regimen in

Cure rates for non–small-cell lung cancer (NSCLC) remain low and the prognosis for patients with even stage IA disease is poor. Complete surgical resection is still the first-line treatment for NSCLC, but many investigators

Malignant pleural mesothelioma is an aggressive tumor associated with exposure to asbestos. Although this disease is rare, with an annual incidence in the United States of 2,000 to 3,000 cases, a steady rise in cases has

WASHINGTON-Overall incidence and mortality rates for cancer continue to decline in the United States. However, a new report finds considerable disparities among racial and ethnic groups, and it warns that a resurgence of smoking among teen-agers forewarns of a likely reversal of the downward trend, especially for lung cancer.

In patients with endobronchial obstruction due to locally advanced lung cancer, photodynamic therapy (PDT) with porfimer

A study published in a recent issue of the International Journal of Radiation Oncology, Biology, and Physics found that elderly patients with limited small-cell lung cancer (SCLC) can tolerate radiation and should not be denied potentially curative